Literature DB >> 25956014

Advances in basic and clinical immunology in 2014.

Javier Chinen1, Luigi D Notarangelo2, William T Shearer3.   

Abstract

Genetic identification of immunodeficiency syndromes has become more efficient with the availability of whole-exome sequencing, expediting the identification of relevant genes and complementing traditional linkage analysis and homozygosity mapping. New genes defects causing immunodeficiency include phophoglucomutase 3 (PGM3), cytidine 5' triphosphate synthase 1 (CTPS1), nuclear factor κB-inducing kinase (NIK), cytotoxic T lymphocyte-associated antigen 4 (CTLA4), B-cell chronic lymphocytic leukemia/lymphoma 10 (BCL10), phosphoinositide-3 kinase regulatory subunit 1 (PIK3R1), IL21, and Jagunal homolog 1 (JAGN1). New case reports expanded the clinical spectrum of gene defects. For example, a specific recombination-activating gene 1 variant protein with partial recombinant activity might produce Omenn syndrome or a common variable immunodeficiency phenotype. Central and peripheral B-cell tolerance was investigated in patients with several primary immunodeficiencies, including common variable immunodeficiency and Wiskott-Aldrich syndrome, to explain the occurrence of autoimmunity and inflammatory disorders. The role of IL-12 and IL-15 in the enhancement of natural killer cell activity was reported. Newborn screening for T-cell deficiency is being implemented in more states and is achieving its goal of defining the true incidence of severe combined immunodeficiency and providing early treatment that offers the highest survival for these patients. Definitive treatment of severe immunodeficiency with both hematopoietic stem cell transplantation and gene therapy was reported to be successful, with increasing definition of conditions needed for optimal outcomes. Progress in HIV infection is directed toward the development of an effective vaccine and the eradication of hidden latent virus reservoirs.
Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HIV1; Immunology; common variable immunodeficiency; dedicator of cytokinesis 8; intravenous immunoglobulin; newborn screening; primary immunodeficiency; recombination-activating gene 1; severe combined immunodeficiency

Mesh:

Year:  2015        PMID: 25956014     DOI: 10.1016/j.jaci.2015.02.037

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  6 in total

1.  Resolution of Multifocal Epstein-Barr Virus-Related Smooth Muscle Tumor in a Patient with GATA2 Deficiency Following Hematopoietic Stem Cell Transplantation.

Authors:  Mark Parta; Jennifer Cuellar-Rodriguez; Alexandra F Freeman; Juan Gea-Banacloche; Steven M Holland; Dennis D Hickstein
Journal:  J Clin Immunol       Date:  2016-12-06       Impact factor: 8.317

2.  Clinical Challenges: Identification of Patients With Novel Primary Immunodeficiency Syndromes.

Authors:  David Buchbinder; Mikko Seppanen; V Koneti Rao; Gulbu Uzel; Diane Nugent
Journal:  J Pediatr Hematol Oncol       Date:  2018-07       Impact factor: 1.289

Review 3.  An Update on the Use of Immunomodulators in Primary Immunodeficiencies.

Authors:  Pandiarajan Vignesh; Amit Rawat; Surjit Singh
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

4.  Editorial: Current Challenges in Immune and Other Acquired Cytopenias of Childhood.

Authors:  Sujal Ghosh; Markus G Seidel
Journal:  Front Pediatr       Date:  2016-02-02       Impact factor: 3.418

Review 5.  Flow Cytometry Contributions for the Diagnosis and Immunopathological Characterization of Primary Immunodeficiency Diseases With Immune Dysregulation.

Authors:  Otavio Cabral-Marques; Lena F Schimke; Edgar Borges de Oliveira; Nadia El Khawanky; Rodrigo Nalio Ramos; Basel K Al-Ramadi; Gesmar Rodrigues Silva Segundo; Hans D Ochs; Antonio Condino-Neto
Journal:  Front Immunol       Date:  2019-11-26       Impact factor: 7.561

6.  Association of serum chemokine ligand 21 levels with asthma control in adults.

Authors:  Yueyan Lou; Yu Zheng; Yanhua Xu; Hui Lu; Yiwei Wang; Yinshi Guo
Journal:  Clinics (Sao Paulo)       Date:  2021-01-20       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.